

Table S1 The correlations between CDKN2A expression and clinicopathological parameters

Characteristics	Low expression of CDKN2A	High expression of CDKN2A	P value
n	322	322	
Pathologic N stage, n (%)			0.008
N0	200 (31.2%)	168 (26.2%)	
N1/N2	119 (18.6%)	153 (23.9%)	
Pathologic stage, n (%)			0.031
I/II	187 (30%)	162 (26%)	
III/IV	123 (19.7%)	151 (24.2%)	
Lymphatic invasion, n (%)			< 0.001
No	204 (35.1%)	146 (25.1%)	
Yes	86 (14.8%)	146 (25.1%)	

Table S2 The correlations between DLAT expression and clinicopathological parameters

Characteristics	Low expression of DLAT	High expression of DLAT	P value
n	322	322	
Pathologic N stage, n (%)			0.003
N0	165 (25.8%)	203 (31.7%)	
N1/N2	154 (24.1%)	118 (18.4%)	
Pathologic stage, n (%)			0.011
I/II	158 (25.4%)	191 (30.7%)	
III/IV	152 (24.4%)	122 (19.6%)	
Lymphatic invasion, n (%)			< 0.001
No	158 (27.1%)	192 (33%)	
Yes	138 (23.7%)	94 (16.2%)	

Table S3 Results of differential expression of CDKN2A and DLAT in GSE21510 and GSE41328

Datasets	Genes	95% confidence interval (95% CI)	P value	Statistical test
GSE21510	CDKN2A	0.20513 to 0.54211	5.74e-05	Independent-sample <i>t</i> -test
GSE21510	DLAT	-1.1663 to -0.44675	0.0008	Wilcoxon rank-sum test
GSE41328	CDKN2A	2.9585 to 3.857	1.53e-10	Welch <i>t</i> -test
GSE41328	DLAT	-0.78595 to -0.026095	0.0383	Welch <i>t</i> -test